Ammar Mushtaq, MD
Internal Medicine · Roswell, NMNPI 1902459704
Payments from drug & device makers
Across 10 payments — averaging $18.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$36
- Exact Sciences$25
- Daiichi Sankyo Inc.$23
- Karyopharm Therapeutics Inc.$19
- Takeda Pharmaceuticals U.S.A., Inc.$18
- Lundbeck LLC$18
- plus $45 from 3 others
What the payments were for
- Food & beverage$185100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $36 |
| Exact Sciences | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Karyopharm Therapeutics Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $18 |
| AbbVie | 1 | $15 |
| Coherus Oncology, Inc. | 1 | $15 |
| Novartis | 1 | $15 |
How this compares
$185 in reported general payments places this provider in the 65th percentile of 578 internal medicine providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 40 | $58,934 |
| JardianceEmpagliflozin | 40 | $38,362 |
| EliquisApixaban | 30 | $34,921 |
| MounjaroTirzepatide | 21 | $25,933 |
| XareltoRivaroxaban | 17 | $21,214 |
| OzempicSemaglutide | 15 | $17,846 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 25 | $9,777 |
| MyrbetriqMirabegron | 12 | $9,590 |
| Losartan Potassium | 251 | $3,244 |
| Atorvastatin Calcium | 276 | $2,753 |
| Tamsulosin Hcl | 149 | $2,525 |
| Levothyroxine Sodium | 212 | $2,506 |
| Arnuity ElliptaFluticasone Furoate | 12 | $2,347 |
| Levemir FlexpenInsulin Detemir | 13 | $2,332 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $2,086 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Roswell
- Michelle ValentineAlbuquerque$12.7M
- Linda GorgosSanta Fe$4.4M
- Edward LewieckiAlbuquerque$1.5M
- Lance RudolphAlbuquerque$980K
- Yordan Orive GomezArtesia$611K
- Michelle IandiorioAlbuquerque$349K
- Nour Ass'adAlbuquerque$332K
- Joao TeixeiraAlbuquerque$259K
- Dulcinea QuintanaAlbuquerque$154K
- Gulshan ParasherAlbuquerque$145K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.